Adel Kardosh, Ph.D.
Affiliations: | 2007 | Molecular Microbiology & Immunology: Doctor of Philosophy | University of Southern California, Los Angeles, CA, United States |
Area:
Molecular Biology, PharmacyGoogle:
"Adel Kardosh"Parents
Sign in to add mentor| Axel H. Schonthal | grad student | 2007 | USC | |
| (Identification of the targets required for the anti-tumor effect of celecoxib and its non-COX-2 inhibitory derivative.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sallets A, Robinson S, Kardosh A, et al. (2018) Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. Blood Advances. 2: 2230-2241 |
| Czerwinski DK, Long SR, Khodadoust M, et al. (2016) Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients Blood. 128: 2947-2947 |
| Ladner RD, Kahn M, Yang D, et al. (2013) Risk of tumor-related death in stage I-III colon cance based on gender and tumor location. Journal of Clinical Oncology. 31 |
| Schultheis AM, Volz NB, Zhang W, et al. (2013) Use of genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with cetuximab-based therapy. Journal of Clinical Oncology. 31: 3567-3567 |
| Volz NB, Zhang W, Yang D, et al. (2013) Use of genetic variants in pericyte-driven tumor vessel maturation genes to predict treatment efficacy in mCRC patients treated with FOLFIRI/bevacizumab. Journal of Clinical Oncology. 31: 3566-3566 |
| Virrey JJ, Liu Z, Cho HY, et al. (2010) Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. Molecular Cancer Therapeutics. 9: 631-41 |
| Golden EB, Lam PY, Kardosh A, et al. (2009) Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 113: 5927-37 |
| Chuang HC, Kardosh A, Gaffney KJ, et al. (2008) COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro Molecular Cancer. 7 |
| Kardosh A, Golden EB, Pyrko P, et al. (2008) Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Research. 68: 843-51 |
| Pyrko P, Kardosh A, Schönthal AH. (2008) Celecoxib transiently inhibits cellular protein synthesis. Biochemical Pharmacology. 75: 395-404 |